Quarterly ResultAug 6, 2026, 08:18 AM
Corbus Pharma Q2 Net Loss $35M; CRB-701 Study Cleared; CRB-913 Data Soon
AI Summary
Corbus Pharmaceuticals reported a net loss of $35.0 million for the second quarter of 2026, an increase from $17.7 million in the same period last year, primarily due to higher clinical development expenses including a $10.0 million milestone payment. The company announced FDA clearance to proceed with the TEMPO-1 registrational study of CRB-701 for oropharyngeal cancer, with enrollment expected to begin in September 2026. Additionally, the Phase 1b CANYON-1 study of CRB-913 for obesity concluded, with topline data anticipated in September 2026. Corbus also strengthened its leadership team with several key appointments.
Key Highlights
- Q2 2026 net loss was $35.0 million, compared to $17.7 million in Q2 2025.
- Q2 2026 net loss per basic and diluted share was $1.81, up from $1.44 in Q2 2025.
- Operating expenses increased to $36.2 million in Q2 2026, from $19.2 million in Q2 2025.
- Cash, cash equivalents, and investments totaled $117.9 million as of June 30, 2026.
- FDA cleared TEMPO-1 registrational study for CRB-701; enrollment starts September 2026.
- CANYON-1 Phase 1b study for CRB-913 concluded; topline data expected September 2026.
- New Chief Medical Officer, Chief Business Officer, and Board Member were appointed.
Price Impact
More from CRBP